论文部分内容阅读
卡托普利由于能抑制血管紧张素转换酶的生物化学转换作用而用于治疗高血压病。本文应用常州制药厂生产的卡托普利治疗7例原发性高血压病人,观察肾素(RA)-血管紧张素转换酶(ACE)-血管紧张素Ⅱ(ATⅡ)系统对卡托普利作用的连续反应。资料与方法 7例中,男4例,女3例;年龄37～60岁,平均46岁。均经临床诊断为Ⅰ～Ⅱ期高血压。全部病人均停用一切药物2周。于服用卡托普利以前作临床及实验室各项常规检查。服药当天,空腹抽肘静脉血测RA、ATⅡ和ACE作对照,并同时连续3次卧位测右肱动脉血压,取平均值。分别于口服卡托普利25
Captopril is used to treat hypertension because it inhibits the biochemical conversion of angiotensin-converting enzyme. In this paper, captopril produced in Changzhou Pharmaceutical Factory was used to treat seven patients with essential hypertension. The effects of renin-angiotensin converting enzyme (ACE) -Angiotoxin Ⅱ (ATⅡ) Continuous reaction of the role. Materials and Methods 7 cases, 4 males and 3 females; aged 37 to 60 years, mean 46 years. All were clinically diagnosed as stage Ⅰ ~ Ⅱ hypertension. All patients discontinued all medication for 2 weeks. Before taking captopril for clinical and laboratory routine examination. The day of medication, fasting elbow vein blood test RA, AT Ⅱ and ACE as a control, and at the same time 3 consecutive position measured right brachial artery blood pressure, taking the average. Respectively, in the oral captopril 25